Biotech News

Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc.

Dyne Therapeutics (DYN)Dyne TherapeuticsCompany update

- Up to $125 million in additional borrowing capacity provides further strategic flexibility - - $50 million of additional capacity funded at amendment closing - WALTHAM, Mass., June 17, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering

Related news

Dyne Therapeutics

Oligonucleotide Therapeutics Dyne Therapeutics develops targeted oligonucleotide medicines for genetically driven muscle diseases. Its FORCE platform links therapeutic payloads to antibodies intended to improve delivery into muscle tissue. Duchenne Muscular Dystrophy Z-rostudirsen is designed for patients with Duchenne muscular dystrophy...

Recent company news

Stock data

Close
26.10 USD
Market cap
2.85B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States